EUVIMEDEUVIMED entdecken
Crossref

Autotaxin inhibition mitigates chronic kidney disease by reducing renal tubular lysosome–mitochondria stress and suppressing fibroblast activation

Seong Woo Lee, Seung Seob Son, Kyung Hoon Na, Se Hun Park, Jina Lee, Sang Hee Lee, Ji-Hye Lee, Eun Young Lee

Kidney Research and Clinical Practice · 05.11.2026

DOI: 10.23876/j.krcp.26.212 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kidney Research and Clinical Practice, online erschienen am 05.11.2026. Verfasst von Seong Woo Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Republic of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Autotaxin (ATX) catalyzes lysophosphatidic acid (LPA) production and has been implicated in fibrotic diseases. However, its role in chronic kidney disease (CKD), particularly its spatial distribution and association with tubular injury, and its contribution to cellular remodeling remains unclear. This study investigated the therapeutic effects and potential mechanisms of autotaxin inhibition (ATXi) in experimental CKD.

Methods

ATX expression and cell type-specific Enpp2 expression were evaluated in CKD mouse models induced by folic acid (FA) or an adenine diet. In a separate intervention study, FA-induced CKD mice were treated with ATXi or vehicle. Renal function, fibrosis, tubular injury, lipid accumulation, and mitochondrial and lysosomal alterations were assessed. In vitro, NRK-49F fibroblasts were treated with transforming growth factor beta (TGF-β) with or without ATXi.

Results

ATX expression was increased in CKD kidneys and was predominantly localized to the tubulointerstitium. ATXi treatment significantly attenuated blood urea nitrogen elevation and tended to reduce cystatin C levels, along with improving tubular injury and interstitial fibrosis, collagen deposition and alpha-smooth muscle actin expression. Renal lipid accumulation and increased LPA receptor mRNA expression observed in CKD were also reduced following ATXi treatment. In addition, ATXi ameliorated tubular mitochondrial structural damage and lysosomal stress. Furthermore, ATXi suppressed TGF-β-induced fibroblast activation and proliferation in vitro.

Conclusion

Pharmacologic inhibition of ATX attenuated CKD, accompanied by improvements in mitochondrial structural abnormalities, modulation of lysosome-associated responses, and suppression of fibroblast activation, thereby reducing tubular injury and renal fibrosis. These findings support a pathogenic role of the ATX-LPA axis in CKD and highlight ATXi as a potential therapeutic target.

Schlagwörter

Stichwörter der Autor:innen

AutotaxinChronic kidney diseaseLysophosphatidic acidMitochondrial dysfunctionRenal fibrosis

Autor:innen und Institutionen

  • Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Republic of Korea.
  • Departments of Medicine and Biomedical Science, Graduate School, Soonchunhyang University, Cheonan, Republic of Korea.
  • Ochang Bio & Environmental Research Institute, Korea Basic Science Institute, Cheongju, Republic of Korea.
  • Department of Pathology, Soonchunhyang University Cheonan Hospital, Cheonan, Republic of Korea.
  • Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Republic of Korea. eylee@sch.ac.kr.
  • Departments of Medicine and Biomedical Science, Graduate School, Soonchunhyang University, Cheonan, Republic of Korea. eylee@sch.ac.kr.

Zitieren

APA

Lee, S. W., Son, S. S., Na, K. H., Park, S. H., Lee, J., Lee, S. H., Lee, J. H., & Lee, E. Y. (2026). Autotaxin inhibition mitigates chronic kidney disease by reducing renal tubular lysosome–mitochondria stress and suppressing fibroblast activation. Kidney Research and Clinical Practice. https://doi.org/10.23876/j.krcp.26.212

Vancouver

Lee SW, Son SS, Na KH, Park SH, Lee J, Lee SH, et al. Autotaxin inhibition mitigates chronic kidney disease by reducing renal tubular lysosome–mitochondria stress and suppressing fibroblast activation. Kidney Research and Clinical Practice. 2026. doi:10.23876/j.krcp.26.212

BibTeX
@article{Lee2026,
  author = {Lee, Seong Woo and Son, Seung Seob and Na, Kyung Hoon and Park, Se Hun and Lee, Jina and Lee, Sang Hee and Lee, Ji-Hye and Lee, Eun Young},
  title = {Autotaxin inhibition mitigates chronic kidney disease by reducing renal tubular lysosome–mitochondria stress and suppressing fibroblast activation},
  journal = {Kidney Research and Clinical Practice},
  year = {2026},
  doi = {10.23876/j.krcp.26.212}
}
Kostenlos starten →